interleukin-6 a new therapeutic target白细胞介素- 6一个新的治疗目标.pdfVIP

Available online /content/8/S2/S5 Proceedings Interleukin-6: a new therapeutic target Josef S Smolen1 and Ravinder N Maini2 1Professor of Medicine, Chairman Division of Rheumatology, Medical University of Vienna, Vienna, Austria 2Emeritus Professor of Rheumatology, The Kennedy Institute of Rheumatology Division, Imperial College, London, UK Corresponding author: Josef S Smolen, josef.smolen@wienkav.at Published: 28 July 2006 Arthritis Research Therapy 2006, 8(Suppl 2):S5 This article is online at /content/8/S2/S5 (doi:10.1186/ar1969) © 2006 BioMed Central Ltd Abstract more of patients with MTX naïve/early RA do not achieve The therapeutic success of biological agents, especially the 50% or better clinical improvement in established disease. tumour necrosis factor (TNF) inhibitors, has opened a new chapter This unmet need for effective interventions in RA clearly in the book of therapies for rheumatoid arthritis. Nevertheless, more mandates further research, especially when the objective, than 50% of patients may not respond by 50% improvement. today, is clinical remission. Nonresponsiveness to TNF New compounds have recently entered the treatment arena. One blockade and/or residual disease activity, as well as the of these is rituximab, which depletes B cells, and another, continuing, albeit slower progression of joint damage in a abatacept, interferes with T-c